XAGE · Longevity Health Holdings Inc.

Despite this revenue momentum, operating income deteriorated to a loss of -$7.1 million, 42% worse than the -$5.0 million loss in FY2024. This widening reflects heightened operating expenses, including a significant ramp-up in selling and marketing efforts tied to the Elevai products, as well as elevated legal and other professional fees related to merger and litigation matters. These investments in growth and necessary professional services, while essential for scaling operations post-acquisition, outpaced gross profit gains and pressured operating margins to -371.6%. Net income showed improvement, narrowing to -$6.9 million from -$10.4 million, or a 33% better result, with diluted EPS at -$4.83 versus -$0.49, indicating some efficiency gains amid the expansion.

Looking ahead, management anticipates that continued revenue from cosmetic product commercialization, combined with cost savings from restructuring, will help extend the cash runway. The company has raised capital successfully in the past but notes no guarantees of future success, potentially requiring measures like curtailing operations if additional funding falters. This going concern context emphasizes the critical need for execution on growth initiatives while navigating litigation and macroeconomic headwinds to achieve sustainable profitability.